within Pharmacolibrary.Drugs.ATC.N;

model N07XX10
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 5e-05,
    adminDuration  = 600,
    adminMass      = 0.6 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.15,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0009166666666666666,
    Tlag           = 2700,            
    Vdp             = 0.095,
    k12             = 6,
    k21             = 6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N07XX10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Laquinimod is an oral immunomodulatory drug that was under investigation for the treatment of multiple sclerosis (MS) and Huntington's disease. It modulates immune responses and neurodegeneration, but development for MS was discontinued after phase III trials due to safety concerns and modest efficacy. It is not approved for clinical use as of 2024.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported in healthy adult volunteers after single and multiple oral dosing.</p><h4>References</h4><ol><li><p>Brück, W, &amp; Zamvil, SS (2012). Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis. <i>Expert review of clinical pharmacology</i> 5(3) 245–256. DOI:<a href=\"https://doi.org/10.1586/ecp.12.12\">10.1586/ecp.12.12</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22697588/\">https://pubmed.ncbi.nlm.nih.gov/22697588</a></p></li><li><p>Elgart, A, et al., &amp; Spiegelstein, O (2019). The effect of laquinimod, a novel immuno-modulator in development to treat Huntington disease, on the pharmacokinetics of ethinylestradiol and levonorgestrel in healthy young women. <i>European journal of clinical pharmacology</i> 75(1) 41–49. DOI:<a href=\"https://doi.org/10.1007/s00228-018-2549-7\">10.1007/s00228-018-2549-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30191262/\">https://pubmed.ncbi.nlm.nih.gov/30191262</a></p></li><li><p>Ziemssen, T, et al., &amp; Hayardeny, L (2017). Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS. <i>Journal of neuroinflammation</i> 14(1) 172–None. DOI:<a href=\"https://doi.org/10.1186/s12974-017-0945-z\">10.1186/s12974-017-0945-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28859672/\">https://pubmed.ncbi.nlm.nih.gov/28859672</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N07XX10;
